Nov. 20th, 2015
Wako Life Sciences names a new president, Mr. Kobayashi.
Wako Life Sciences announces a new president, Mr. Kobayashi, to lead the diagnostics organization effective January 1, 2016. The organization has been successfully led for 10 years by Dr. Satomura. As a visionary leader Dr. Satomura has been instrumental in developing state of the art microfluidic based solutions that have revolutionized diagnostic cancer biomarker Immunoassays with two minute turnaround time. The success of the uTASWako i30 system is credited to unique microfluidic technology development, spearheaded by Dr. Satomura and his team of scientists and engineers. He also led more than 10 clinical studies together with academia and companies to enhance clinical and diagnostic efficiencies of biomarkers.
Dr Satomura will be leaving WLS on December 31, 2015.
Oct. 27th, 2015
HCC surveillance in an era of biomarkers
Doctor Robert G. Gish, a world renowned hepatologist, speaks about the importance of including biomarkers for HCC risk assessment in liver cancer surveillance programs and proposes his current liver surveillance algorithm as a model. To view the presentation:
Clinical Diagnostic and
HCC Biomarkers and
Wako is a comprehensive manufacturer of Clinical Diagnostic reagents that are of the highest quality and good value to performance. Our products are the result of nearly 90 years of dedication to the field of in vitro diagnostics.
For Hepatocellular Carcinoma (HCC) Risk Assessment
Adding the two biomarkers, AFP-L3 and DCP, to your current HCC surveillance practice can increase your chances of detecting early HCC. These tests are available now through major reference laboratories in the United States and Canada.
Wako is a leading manufacturer of the highest quality chemistry reagents worldwide. Our products are the result of over 90 years of dedication to the field of laboratory science and research development. Our superior research reagents are easy to use and have a robust history of utilization in academia.